APSR2026-448

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-011
P11
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1220498-46904-APSR26 JH Park_439912.pdf
Format: PDF Only
07. COPD
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Joo Hun Park * Ajou University School of Medicine Pulmonary and Critical Care Medicine Suwon Korea, ROK (South)
Ju Hyun Oh - Ajou University School of Medicine Pulmonary and Critical Care Medicine Suwon Korea, ROK (South)
Yong Hyun Kim Kim - The Catholic University of Korea Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine Seoul Korea, ROK (South)
Kyungjoo Kim - The Catholic University of Korea Department of Internal Medicine Seoul Korea, ROK (South)
Chin Kook Rhee - The Catholic University of Korea Department of Internal Medicine Seoul Korea, ROK (South)
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Joo Hun
Park
jhpamc@hanmail.net
+82183798299
51-60
 
Original Research
Association Between Inhaler Prescription and COPD-Related Complications in Never-Smokers: A Nationwide Population-Based Study
Maximum 25 words
Abstract Content
A comprehensive real-world comparison of long-acting muscarinic antagonist (LAMA)/long-acting β₂-agonist (LABA) therapy versus inhaled corticosteroid (ICS)/LABA therapy is warranted due to ongoing safety concerns among never-smokers with chronic obstructive pulmonary disease (COPD). Accordingly, we investigated the effects of inhaler prescriptions on COPD-related complications.
We conducted a retrospective observational study using data from the Korean National Health Insurance Service–National Sample Cohort (NHIS-NSC) from January 1, 2002, to December 31, 2019. Eligible participants were adults aged ≥40 years with a diagnosis of COPD, no history of smoking, and a newly initiated inhaler prescription. Patients with a history of cancer during the screening period or those who switched inhalers after the index date were excluded. Outcomes were compared between two groups: the LAMA/LABA group (n = 382; mean age, 73.0 ± 10.9 years) and the ICS/LABA group (n = 1,780; mean age, 75.4 ± 11.9 years). Complication rates were expressed as events per 1,000 patient-years.
Compared with the LAMA/LABA group, the ICS/LABA group had significantly higher rates of hospitalization (49.9 vs. 54.6, p < 0.01), ischemic heart disease (24.1 vs. 31.6, p < 0.01), cerebrovascular disease (17.5 vs. 26.1, p < 0.01), and mortality (8.0 vs. 17.1, p < 0.01). The rate of bacterial pneumonia tended to be higher in the ICS/LABA group than in the LAMA/LABA group (43.2 vs. 40.1, p = 0.062). No significant differences were observed between the groups in rates of emergency room visits, viral pneumonia, heart failure, or pulmonary embolism.
In never-smokers with COPD, ICS/LABA therapy, compared with LAMA/LABA therapy, was associated with an increased risk of adverse outcomes, including higher rates of hospitalization, ischemic heart disease, cerebrovascular disease, and mortality.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
COPD, complication, never-smokers
maximum 3 keywords and no abbreviations, separated by commas
None
296